Our modeling efforts predicted higher levels of effector responses in both the LP and the GLN when deleting PPARγ, thus highlighting the role of PPARγ activation as a potential mechanism for modulating CD4+ T cell responses during bacterial infection and positioning PPARγ as a candidate for immunotherapeutics development. This evidence concerns the gene PPARG and bacterial infectious disease.